28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
25 Apr
BIOPOR
  Ønsket har i mange år været at få de store diagnostiske producenter i verden  til at distribuere N..
29
26 Apr
FING-B
Jeg giver dig ret, Taastrup. Alle jer der konstant har travlt med at nedgøre Taastrup - I skulle..
27
30 Apr
OMXC20CAP
Sell in may, and go ...   Det er blevet tid til en mindre opdatering. Jeg har været bortrejst, og sa..
23
28 Apr
BAVA
Så fik jeg pløjet data ind i et excelark, og her er konklussionerne:   data kommer fra et forsøg, hv..
18
28 Apr
MAERSK-A
Københavns Kommune agter jfr DR.DK + i Børsen.dk 27/4 at sælge sine Mærsk aktier pga , at mærsk ikke..
14
26 Apr
SUNEQ
Dommer Stuart Bernstein som styre Chapter 11 retssagen ved U.S. Bankruptcy Court på Manhattan’en hav..
14
01 May
BAVA
Bavarian bliver ikke opkøbt. Stop nu med jeres drømme og løgne og bilde folk dette ind. Hvornår har ..
12
01 May
NOVO-B
Hvad fanden har EI gang i, hvis Alpehue har fået karantæne grundet ham stalkeren hansfrak12 ?   Jeg ..
12
01 May
 
“The Big Five” hvor en er « gone missing»                  Ifølge det dokumnentet (DIP dokumentet), ..
12
27 Apr
FING-B
CrowHater   Fingerprint Cards / Crowhater / Analytiker har noll förståelse för pengar... I dag 10:48..
12

Rathbone Brothers Plc : Director/PDMR Shareholding

29/04/2016 15:31:03
Rathbone Brothers Plc Director and PDMR Shareholding The Rathbone Savings Related Share Option Plan On 29 April 2016, options over Rathbone Brothers ..

Novae Group plc: Holdings in Company

29/04/2016 12:41:31
  TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi   ..

Majedie Asset Management Ltd : Form 8.3 - HOME RETAIL GROUP

29/04/2016 10:35:51
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTI..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
AIR FRANCE - KLM : The Air France KLM Board of Directors designates Jean-Marc Janaillac as the group's future Chairman and CEO
2
OCEANTEAM ASA - ANNUAL REPORT 2015
3
Faiveley Transport and Wabtec meet with the European Commission - Closing expected in Q4 2016
4
Veidekke ASA: PRESENTATION OF FIRST QUARTER RESULTS 2016
5
Aéroports de Paris: First quarter of 2016 consolidated revenue up by 1.8%, to €683 million

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
02 May 2016 13:35:40
(UTC) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20160421.1 - EUROWEB7 - 2016-05-02 14:35:40 - 2016-05-02 13:35:40 - 1000 - Website: OKAY